Cite
MLA Citation
P.J. Mease et al.. “THU0325 Secukinumab demonstrates a consistent safety profile with up to 5 years treatment in patients with psoriatic arthritis and moderate to severe plaque psoriasis: updated pooled safety analyses.” Annals of the rheumatic diseases, vol. 77, n.d., pp. 381–382. http://access.bl.uk/ark:/81055/vdc_100144727009.0x00004f